TabletsClinical Overview
Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
CRITICAL ADMINISTRATION DIRECTIVE: Take orally ONCE WEEKLY on the same day each week with water, with or without food. Daily dosing for rheumatoid arthritis or psoriasis is a LETHAL medical error. Daily folic acid supplementation (1 to 5 mg daily except on the methotrexate dosing day) is recommended to reduce mucosal and gastrointestinal toxicity.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, fatigue, mouth ulcers (stomatitis), headache, mild transaminase rise, alopecia. Rare/Severe: Fatal bone marrow failure (from inadvertent daily dosing), acute interstitial pneumonitis (dry cough, dyspnea), liver fibrosis, and severe cutaneous adverse reactions.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: ONCE WEEKLY DOSING ONLY for rheumatoid arthritis and psoriasis; fatal bone marrow depression occurs if taken daily. Black Box Warning: Extreme teratogenicity and embryotoxicity (Category X); strict contraception required. Monitor CBC, LFTs, and renal function monthly.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.
Methotrexate Tablets 7.5 mg
Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.
Methotrexate Tablets 2.5mg
Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.
Methotrexate Tablets 10mg
Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.
Methotrexate Tablets 5mg
Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.